Thrombotic microangiopathy in renal allografts: The diagnostic challenge

Current Opinion in Organ Transplantation

Volumn 19, Issue 3, 2014, Pages 283-292

  Nadasdy, Tibor ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

histologic diagnosis; renal allografts; thrombotic microangiopathy; transplant kidney biopsy

Indexed keywords

CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEMBRANE COFACTOR PROTEIN; PHOSPHOLIPID ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; GENE MUTATION; GLOMERULOPATHY; GOLD STANDARD; GRAFT RECIPIENT; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; REVIEW; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ALLOGRAFTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; THROMBOTIC MICROANGIOPATHIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84900824811     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000074     Document Type: Review

References (83)

1. Laszik Z, Kambham N, Silva FG. Thrombotic Microangiopathies. In: Jennette JC OJ, Schwartz MM, et al. editor. Heptinstalls Pathology of the Kidney. 7th edn. Philadelphia, PA: Lippincott, Williams, & Wilkins; 2014
2. Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant 2012; 27:2673-2685
3. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:1676-1687
4. Besbas N, Karpman D, Landau D, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70:423-431
5. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013; 33:508-530
6. Noris M, Remuzzi G. Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Semin Nephrol 2010; 30:395-408
7. Bu F, Maga T, Meyer NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014; 25:55-64
8. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10:1517-1523
9. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42:1058-1068
10. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-Associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006; 1:88-99
11. Kavanagh D, Richards A, Goodship T, Jalanko H. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36:653-659
12. Tang W, Mohandas J, McDonald SP, et al. End-stage kidney disease due to haemolytic uraemic syndrome: outcomes in 241 consecutive ANZDATA registry cases. BMC Nephrol 2012; 13:164
13. Seitz B, Albano L, Vocila F, et al. Recurrence of hemolytic uremic syndrome after renal transplantation. Transplant Proc 2007; 39:2583-2585
14. Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008; 12:619-629
15. Cochat P, Fargue S, Mestrallet G, et al. Disease recurrence in paediatric renal transplantation. Pediatr Nephrol 2009; 24:2097-2108
16. Chan MR, Thomas CP, Torrealba JR, et al. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am J Kidney Dis 2009; 53:321-326
17. Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013; 13: 663-675
18. Fremeaux-Bacchi V, Arzouk N, Ferlicot S, et al. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: A role for endothelial microchimerism. Am J Transplant 2007; 7:2047-2051
19. Fremeaux-Bacchi] V, Moulton EA, Kavanagh D, et al. Genetic and functional analyses of membrane cofactor protein [CD46] mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17:2017-2025
20. Bresin E, Rurali E, Caprioli J, et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013; 24:475-486
21. Le Quintrec M, Zuber J, Noel LH, et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant 2009; 9:1223-1229
22. Lorcy N, Rioux-Leclercq N, Lombard ML, et al. Three kidneys, two diseases, one antibody? Nephrol Dial Transplant 2011; 26:3811-3813
23. Waters AM, Pappworth I, Marchbank K, et al. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am J Transplant 2010; 10:168-172
24. Mise K, Ubara Y, Matsumoto M, et al. Long term follow up of congenital thrombotic thrombocytopenic purpura [Upshaw-Schulman syndrome] on hemodialysis for 19 years: A case report. BMC Nephrol 2013; 14:156
25. Veyradier A, Lavergne JM, Ribba AS, et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura [Upshaw-Schulman syndrome]. J Thromb Haemost 2004; 2:424-429
26. Pham PT, Pham PC, Danovitch GM, et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 2005; 5:2565-2569
27. Canaud G, Bienaime F, Noel LH, et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 2010; 10:2051-2060
28. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013; 13:2179-2185
29. Caires RA, Marques ID, Repizo LP, et al. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival. Transplant Proc 2012; 44:2388-2390
30. Satoskar AA, Pelletier R, Adams P, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 2010; 10:1804-1811
31. Schwimmer J, Nadasdy TA, Spitalnik PF, et al. De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41:471-479
32. Randhawa PS, Tsamandas AC, Magnone M, et al. Microvascular changes in renal allografts associated with FK506 [Tacrolimus] therapy. Am J Surg Pathol 1996; 20:306-312
33. Mihatsch MJ, Thiel G, Basler V, et al. Morphological patterns in cyclosporine-treated renal transplant recipients. Transplant Proc 1985; 17:101-116
34. Sibley RK, Rynasiewicz J, Ferguson RM, et al. Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone. Surgery 1983; 94:225-234
35. Young BA, Marsh CL, Alpers CE, Davis CL. Cyclosporine-Associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis 1996; 28:561-571
36. Zent R, Katz A, Quaggin S, et al. Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A. Clin Nephrol 1997; 47: 181-186
37. Zarifian A, Meleg-Smith S, ODonovan R, et al. Cyclosporine-Associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55:2457-2466
38. Remuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989; 13:261-272
39. Tomasiak M, Rusak T, Gacko M, Stelmach H. Cyclosporine enhances platelet procoagulant activity. Nephrol Dial Transplant 2007; 22:1750-1756
40. Morozumi K, Takeda A, Uchida K, Mihatsch MJ. Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology? Transplant Proc 2004; 36:251S-256S
41. Renner B, Klawitter J, Goldberg R, et al. Cyclosporine induces endothelial cell release of complement-Activating microparticles. J Am Soc Nephrol 2013; 24:1849-1862
42. Yilmaz VT, Kocak H, Avci AB, et al. Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient. Int Urol Nephrol 2011; 43:581-584
43. Carmona A, Diaz-Ricart M, Palomo M, et al. Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. Biol Blood Marrow Transplant 2013; 19:1439-1445
44. Habib A, Karmali V, Polavarapu R, et al. Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation. J Am Coll Cardiol 2013; 61:971-980
45. Dormond-Meuwly A, Roulin D, Dufour M, et al. The inhibition of MAPK potentiates the antiangiogenic efficacy of mTOR inhibitors. Biochem Biophys Res Commun 2011; 407:714-719
46. Meehan SM, Kremer J, Ali FN, et al. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. Clin J Am Soc Nephrol 2011; 6:395-403
47. Gonzalez-Roncero F, Suner M, Bernal G, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012; 44:2690-2694
48. Baid S, Pascual M, WilliamsWWJr, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10:146-153
49. Iwami D, Harada H, Hotta K, et al. A case of pregnancy-induced thrombotic thrombocytopenic purpura with a kidney allograft recipient. Clin Transplant 2010; 24:66-69
50. Ardalan MR, Shoja MM, Tubbs RS, Jayne D. Parvovirus B19 microepidemic in renal transplant recipients with thrombotic microangiopathy and allograft vasculitis. Exp Clin Transplant 2008; 6:137-143
51. Brodin-Sartorius] A, Mekki Y, Bloquel B, et al. Parvovirus B19 infection after kidney transplantation. Nephrol Ther 2012; 8:5-12
52. Murer L, Zacchello G, Bianchi D, et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol 2000; 11:1132-1137
53. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. De novo thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss. Am J Nephrol 2010; 32:491-496
54. Rane S, Nada R, Minz M, et al. Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients. Transplant Proc 2012; 44:713-716
55. Le Quintrec M, Lionet A, Kamar N, et al. Complement mutation-Associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008; 8:1694-1701
56. Hochstetler LA, Flanigan MJ, Lager DJ. Transplant-Associated thrombotic microangiopathy: The role of IgG administration as initial therapy. Am J Kidney Dis 1994; 23:444-450
57. Wiener Y, Nakhleh RE, Lee MW, et al. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome. Clin Transplant 1997; 11:157-162
58. Halloran PF, de Freitas DG, Einecke G, et al. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10:2215-2222
59. Mengel M, Campbell P, Gebel H, et al. Precision diagnostics in transplantation: from bench to bedside. Am J Transplant 2013; 13:562-568
60. Drachenberg CB, Papadimitriou JC. Endothelial injury in renal antibodymediated allograft rejection: A schematic view based on pathogenesis. Transplantation 2013; 95:1073-1083
61. Agustian PA, Bockmeyer CL, Modde F, et al. Glomerular mRNA expression of prothrombotic and antithrombotic factors in renal transplants with thrombotic microangiopathy. Transplantation 2013; 95:1242-1248
62. Haas M. Transplant glomerulopathy: its not always about chronic rejection. Kidney Int 2011; 80:801-803
63. Husain S, Sis B. Advances in the understanding of transplant glomerulopathy. Am J Kidney Dis 2013; 62:352-363
64. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody- mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7:1743-1752
65. Baid-Agrawal S, Farris AB 3rd, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80:879-885
66. Ivanyi B, Kemeny E, Szederkenyi E, et al. The value of electron microscopy in the diagnosis of chronic renal allograft rejection. Mod Pathol 2001; 14: 1200-1208
67. Haas M, Mirocha J. Early ultrastructural changes in renal allografts: correlation with antibody mediated rejection and transplant glomerulopathy. Am J Transplant 2011; 11:2123-2131
68. Wavamunno MD, OConnell PJ, Vitalone M, et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007; 7:2757-2768
69. Koppula S, Yost SE, Sussman A, et al. Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients. Clin Transplant 2013; 27:591-597
70. Cicora F, Paz M, Mos F, Roberti J. Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy. Case Rep Med 2013; 2013: 260254
71. Ashman N, Chapagain A, Dobbie H, et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant 2009; 9:424-427
72. Satoskar AA, Pelletier R, Nadasdy GM, et al. Histopathology and outcome of acute humoral rejection in renal allografts. Front Biosci 2011; 3:919-928
73. Schmidtko J, Peine S, El-Housseini Y, et al. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: A focus on eculizumab. Am J Kidney Dis 2013; 61:289-299
74. Zuber J, Le Quintrec M, Morris H, et al. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev 2013; 27:117-125
75. Xie L, Nester CM, Reed AI, et al. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: A case report. Transplant Proc 2012; 44:3037-3040
76. Commereuc M, Karras A, Amrein C, et al. Successful treatment of acute thrombotic microangiopathy by eculizumab after combined lung and kidney transplantation. Transplantation 2013; 96:e58-e59
77. Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12:3337-3354
78. Roman-Ortiz E, Mendizabal Oteiza S, Pinto S, et al. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr Nephrol 2014; 29:149-153
79. Pelicano MB, de Cordoba SR, Diekmann F, et al. Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation. Transplantation 2013; 96:e26-e29
80. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011; 11:2523-2527
81. Wilson CH, Brown AL, White SA, et al. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011; 92:e42-e43
82. Brodsky SV, Satoskar A, Nadasdy T. Endothelial microparticles in transplant patients: great potential but a long way to go. Front Biosci (Elite Ed) 2012; 4:876-888
83. Saland JM, Shneider BL, Bromberg JS, et al. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4:201-206.